Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction

Epilepsia

Volumn 41, Issue 11, 2000, Pages 1420-1431

  Harding, G F A ^a   Wild, J M ^a   Robertson, K A ^a   Lawden, M C ^b   Betts, T A ^c   Barber, C ^d   Barnes, P M F ^e  

^a ASTON UNIVERSITY   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e Aventis Pharmaceuticals   (United Kingdom)

Author keywords

Electro oculogram; Electroretinogram; Vigabatrin; Visual field; Visual evoked potential

Indexed keywords

VIGABATRIN;

ADULT; ANALYZER; ARTICLE; CLINICAL ARTICLE; ELECTROOCULOGRAPHY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MALE; OSCILLATORY POTENTIAL; PHOTOPIC VISION; PRIORITY JOURNAL; RETINA; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 0033761344     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb00117.x     Document Type: Article

References (34)

1. Severe persistent visual field constriction associated with vigabatrin
2. Vigabatrin therapy for resistant partial epilepsies
3. Severe persistent visual field constriction associated with vigabatrin: Four possible mechanisms exist
4. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings
5. Outer retinal dysfunction in patients treated with vigabatrin
6. Symptomatic and asymptomatic visual loss in patients taking vigabatrin
7. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field constriction
8. Visual field defects associated with vigabatrin therapy
9. Characteristics of a unique visual field defect attributed to vigabatrin
10. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiological findings
11. Cerebrospinal fluid GABA and seizure control with vigabatrin
12. A multicentre study of vigabatrin for drug resistant epilepsy
13. The effect of different vigabatrin treatment regimes on CSF biochemistry and seizure control in epileptic patients
14. Response to vigabatrin in relation to seizure type
15. Vigabatrin vs carbamazepine in patients with newly diagnosed epilepsy
16. Neuropathology of vigabatrin
17. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy
18. Evoked potential monitoring of vigabatrin patients
19. Effects of vigabatrin on evoked potentials in epileptic patients
20. Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients
21. Electroretinogram, pattern electroretinogram and visual evoked potential assessment in patients receiving vigabatrin
22. No effect of long-term vigabatrin treatment on CNS conduction in epileptic patients: Results of a multicenter study of somatosensory and visual evoked potentials
23. Recommended standards for electroretinograms and visual evoked potentials: Report of an IFCN committee
24. Standard for visual evoked potentials
25. Guidelines for basic pattern electroretinography
26. Analysis of the electro-oculograms of a series of normal subjects: Role of the lens in the development of the standing potential
27. The field topography of ERG components in man. 1. The photopic luminance response
28. Visual electrophysiological effect of a GABA transaminase blocker
29. Electroretinographic changes are not associated with loss of visual function in paediatric patients following treatment with vigabatrin
30. Retinal physiology
31. Effects of GABA on horizontal cells in the tiger salamander retina
32. Functional role of GABA in cat retina. I. Effects of GABA agonists
33. Vivoaction of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs brain
34. Immunocytochemical evidence that vigabatrin in rats cause GABA accumulation in glial cells of the retina